Scinai Immunotherapeutics reported a net income of $1.6 million for H1 2026, a significant improvement from a $4.1 million loss in the prior year. This positive net income was primarily driven by a $6.4 million bargain purchase gain from the acquisition of Recipharm Israel, rather than operational performance, as the company still reported an operating loss and increased cost of revenues.
Scinai Immunotherapeutics reported a net income of $1.6 million for the first half of 2026, a notable improvement from a $4.1 million loss in the prior year. However, this positive net income is primarily attributable to a non-operating $6.4 million bargain purchase gain from the acquisition of Recipharm Israel. Operationally, the company saw increased revenues but also significantly higher cost of revenues, leading to an expanded gross loss and operating loss. This indicates that while the acquisition provided a one-time financial boost, the underlying CDMO business is still in a growth phase with increasing costs as facility utilization ramps up. Traders should note the distinction between the reported net income and the operational performance, as the latter still shows challenges in profitability despite revenue growth and committed customer orders. The long-term implication hinges on the company's ability to convert committed orders into profitable revenue and improve operational efficiency.